Here are the S-3 shelf registrations from InMed Pharmaceuticals Inc. (INM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow INM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INM filings page.
$50,000,000 registration: InMed Pharmaceuticals Inc. has filed a shelf prospectus to offer and sell, from time to time, up to $50,000,000 of common shares, preferred shares, warrants, subscription rights and units, in one or more offerings. The prospectus permits sales in any combination and contemplates sales through underwriters, dealers, agents or directly on a continuous or delayed basis.
The filing states the aggregate market value of common shares held by non-affiliates was approximately $2.6 million based on March 18, 2026 closing price of $0.88 and 2,915,074 non-affiliate shares. The audit reports for fiscal years ended June 30, 2025 and June 30, 2024 include explanatory going-concern paragraphs.